Literature DB >> 29931364

Convection-Enhanced Delivery of Muscimol Into the Bilateral Subthalamic Nuclei of Nonhuman Primates.

John D Heiss1, Stuart Walbridge1, Davis P Argersinger1, Christopher S Hong1,2, Abhik Ray-Chaudhury1, Russell R Lonser1,3, W Jeffrey Elias4, Kareem A Zaghloul1.   

Abstract

BACKGROUND: Muscimol is a gamma-aminobutyric acid receptor agonist that selectively and temporarily inhibits neurons. Local bolus injection of muscimol has been used experimentally to inhibit neuronal populations within discrete anatomical structures and discern their physiological function.
OBJECTIVE: To determine the safety and behavioral effects of convection-enhanced delivery of muscimol into the bilateral subthalamic nuclei (STN) of nonhuman primate rhesus macaques (NHPs).
METHODS: Six awake NHPs underwent co-infusion of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA), a surrogate magnetic resonance imaging (MRI) tracer, with increasing concentrations of muscimol for behavioral and histological assessment. Three other NHPs were co-infused with Gd-DTPA and 3H-muscimol into the STN to determine muscimol distribution by MRI and autoradiography. Two NHPs underwent microcatheter implantation without muscimol infusion for control comparison.
RESULTS: MRI revealed selective and complete perfusion of the bilateral STN in animals infused with Gd-DTPA and muscimol. No abnormal movements occurred at 0.125 mM. Muscimol doses between 0.25 and 4.4 mM resulted in transient, dose-dependent hyperkinesia. Muscimol (8.8 mM) resulted in severe bilateral dyskinesias, ballistic movements, and sedation. An 88.8 mM dose produced unresponsiveness in 1 animal. Infusion-related pathological abnormities or toxicity was not present on histological examination. MRI distribution of co-infused Gd-DTPA was similar to autoradiographic distribution of 3H-muscimol (Vd; R = 0.94). Mean Vd of infused animals was 37.9 mm3 ± 11.7 mm3 and mean Vd: Vi 7.6 ± 2.3.
CONCLUSION: Bilateral convection-enhanced delivery of muscimol into the primate STN resulted in dose-related hyperkinetic movements that resolved after stopping the infusion. Muscimol was not toxic to brain tissue. Gd-DTPA accurately tracked muscimol distribution. © Published by Oxford University Press on behalf of Congress of Neurological Surgeons 2017.

Entities:  

Keywords:  Convection; Muscimol; Parkinson's disease; Primates; Subthalamus

Mesh:

Substances:

Year:  2019        PMID: 29931364      PMCID: PMC6702416          DOI: 10.1093/neuros/nyy279

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  27 in total

1.  Animal research: reporting in vivo experiments--the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  J Cereb Blood Flow Metab       Date:  2011-01-05       Impact factor: 6.200

2.  Dysfunction of the subthalamic nucleus induces behavioral and movement disorders in monkeys.

Authors:  Carine Karachi; David Grabli; Nicolas Baup; Stéphanie Mounayar; Dominique Tandé; Chantal François; Etienne C Hirsch
Journal:  Mov Disord       Date:  2009-06-15       Impact factor: 10.338

3.  Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer.

Authors:  Ashok R Asthagiri; Stuart Walbridge; John D Heiss; Russell R Lonser
Journal:  J Neurosurg       Date:  2011-05-27       Impact factor: 5.115

4.  Equilibrium binding characteristics of [3H]thiomuscimol.

Authors:  B Ebert; B Frølund; N H Diemer; P Krogsgaard-Larsen
Journal:  Neurochem Int       Date:  1999-05       Impact factor: 3.921

5.  Convection-enhanced delivery of M13 bacteriophage to the brain.

Authors:  Alexander Ksendzovsky; Stuart Walbridge; Richard C Saunders; Ashok R Asthagiri; John D Heiss; Russell R Lonser
Journal:  J Neurosurg       Date:  2012-05-18       Impact factor: 5.115

6.  Local distribution and toxicity of prolonged hippocampal infusion of muscimol.

Authors:  John D Heiss; Stuart Walbridge; Paul Morrison; Robert R Hampton; Susumu Sato; Alexander Vortmeyer; John A Butman; James O'Malley; Param Vidwan; Robert L Dedrick; Edward H Oldfield
Journal:  J Neurosurg       Date:  2005-12       Impact factor: 5.115

7.  Image-guided convection-enhanced delivery of muscimol to the primate brain.

Authors:  John D Heiss; Stuart Walbridge; Ashok R Asthagiri; Russell R Lonser
Journal:  J Neurosurg       Date:  2010-04       Impact factor: 5.115

Review 8.  Movement disorders following lesions of the thalamus or subthalamic region.

Authors:  M S Lee; C D Marsden
Journal:  Mov Disord       Date:  1994-09       Impact factor: 10.338

9.  Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum.

Authors:  Yasushi Shimo; Thomas Wichmann
Journal:  Eur J Neurosci       Date:  2008-12-12       Impact factor: 3.386

10.  Effects of transient focal inactivation of the basal ganglia in parkinsonian primates.

Authors:  Mark S Baron; Thomas Wichmann; Demin Ma; Mahlon R DeLong
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

View more
  4 in total

1.  Convection-enhanced delivery of botulinum toxin serotype A into the nonhuman primate cisterna magna and hippocampus.

Authors:  Davis P Argersinger; Stuart Walbridge; Nicholas M Wetjen; Alexander O Vortmeyer; Tianxia Wu; John A Butman; John D Heiss
Journal:  J Neurosurg       Date:  2019-07-19       Impact factor: 5.115

Review 2.  Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.

Authors:  Manuela Gernert; Malte Feja
Journal:  Pharmaceutics       Date:  2020-11-24       Impact factor: 6.321

3.  An On-Demand Drug Delivery System for Control of Epileptiform Seizures.

Authors:  Takashi Nakano; Shakila B Rizwan; David M A Myint; Jason Gray; Sean M Mackay; Paul Harris; Christopher G Perk; Brian I Hyland; Ruth Empson; Eng Wui Tan; Keshav M Dani; John Nj Reynolds; Jeffery R Wickens
Journal:  Pharmaceutics       Date:  2022-02-21       Impact factor: 6.321

Review 4.  Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience.

Authors:  Pavan S Upadhyayula; Eleonora F Spinazzi; Michael G Argenziano; Peter Canoll; Jeffrey N Bruce
Journal:  Pharmaceutics       Date:  2020-12-30       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.